RITUXIMAB IN SUBJECTS WITH ISN/RPS CLASS III OR IV LUPUS NEPHRITIS

利妥昔单抗用于 ISN/RPS III 或 IV 级狼疮性肾炎患者

• 批准号: 7605248
• 负责人: ELIZA F CHAKRAVARTY
• 金额: $ 0.06万
• 依托单位: STANFORD UNIVERSITY
• 依托单位国家: 美国
• 财政年份: 2007
• 资助国家: 美国
• 起止时间: 2007-02-15 至 2007-11-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7605248
• 关键词: B-Lymphocytes; Class; Computer Retrieval of Information on Scientific Projects Database; Funding; Grant; Inflammation; Institution; Lupus; Lupus Nephritis; Monoclonal Antibodies; Numbers; Patients; Placebos; Proteins; Purpose; Research; Research Personnel; Resources; Safety; Signs and Symptoms; Source; United States National Institutes of Health; design; mycophenolate mofetil; rituximab

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The purpose of this study is to investigate the safety and efficacy of rituximab in combination with mycophenolate mofetil (MMF) compared with placebo in combination with MMF in the treatment of lupus nephritis. Rituximab is a monoclonal antibody, which is a protein that helps protect the body against foreign materials. It decreases some types of B-cells in the body which may be important in inflammation. Rituximab has been used in a small number of patients with lupus nephritis, and this study is designed to further evaluate whether rituximab would reduce the signs and symptoms of lupus and lupus nephritis.

该子项目是利用该技术的众多研究子项目之一 资源由 NIH/NCRR 资助的中心拨款提供。子项目及 研究者 (PI) 可能已从 NIH 的另一个来源获得主要资金， 因此可以在其他 CRISP 条目中表示。列出的机构是 中心，不一定是研究者的机构。 本研究的目的是探讨利妥昔单抗联合吗替麦考酚酯（MMF）与安慰剂联合MMF治疗狼疮性肾炎的安全性和有效性。 利妥昔单抗是一种单克隆抗体，是一种有助于保护身体免受异物侵害的蛋白质。 它会减少体内某些类型的 B 细胞，这可能对炎症很重要。 利妥昔单抗已用于少数狼疮性肾炎患者，本研究旨在进一步评估利妥昔单抗是否会减轻狼疮和狼疮性肾炎的体征和症状。